Concept Life Sciences appoints Philip Payne as Chief Commercial Officer
News Oct 24, 2017
Concept Life Sciences announced it has appointed Philip Payne as Chief Commercial Officer, to support the group’s continued growth. Philip completes Concept’s leadership team, following the appointment in August of John Handley as COO.
Philip will work with Concept’s executive team and board to drive the group’s commercial strategy, leading the business development function and helping to guide the next stage of the Company’s growth. He will be responsible for managing the sales team, including identification of new service areas, geographies and markets, supporting the broadening of Concept’s reach into Europe and the US.
Philip has 27 years’ experience in managing the integration of business development in an international environment, and has gained cross-sector expertise through roles in pharma and biotech discovery as well as analytical and development services. He joins Concept from Aptuit, where he held various roles, including Vice President of Sales, and was responsible for the global business development team and strategic accounts. Prior to joining Aptuit he was Business Development Director Europe and Asia for Sterile Technologies at Catalent Pharma Solutions, and Pharmaceutical Business Development Director with Reading Scientific Services Ltd.
Michael Fort, Executive Chairman, Concept Life Sciences, said: “Philip’s experience in managing multidisciplinary, international teams across a range of industries will be a great asset as Concept’s rapid rate of expansion continues. Following on from John’s appointment as COO, Concept now has an extremely strong leadership team. We are delighted to welcome Philip to the group.”
Philip Payne, Chief Commercial Officer, Concept Life Sciences, said: “I am excited to join Concept at this pivotal stage in the growth of the Company, and look forward to working with the team to meet the group’s commercial and strategic objectives.”
Antitumor Immune Function in Liver Controlled by Gut MicrobiomeNews
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. The study showed that bacteria found in the gut of mice affect the liver’s antitumor immune function. The findings have implications for understanding the mechanisms that lead to liver cancer and for therapeutic approaches to treat them.READ MORE
Tiny Particles Carry Tumor Shrinking Drugs into the BrainNews
MIT researchers have now devised a new drug-delivering nanoparticle that could offer a better way to treat glioblastoma. The particles, which carry two different drugs, are designed so that they can easily cross the blood-brain barrier and bind directly to tumor cells.READ MORE
Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous SclerosisNews
Addressing a critical issue for people with a genetic disorder called tuberous sclerosis complex (TSC), doctors reported that a skin cream containing rapamycin significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with the condition.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018